Genfit Past Earnings Performance
Past criteria checks 3/6
Genfit has been growing earnings at an average annual rate of 38.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 17.2% per year. Genfit's return on equity is 22.9%, and it has net margins of 27.7%.
Key information
38.1%
Earnings growth rate
44.5%
EPS growth rate
Biotechs Industry Growth | 30.8% |
Revenue growth rate | 17.2% |
Return on equity | 22.9% |
Net Margin | 27.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%
Nov 16We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit
Sep 27Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%
Sep 26Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%
Sep 24Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly
Sep 22Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%
May 23Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues
Jan 03Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?
Sep 22Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)
Jul 05Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected
Jun 23We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease
Dec 28New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)
Sep 30Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term
Jun 29Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.
Mar 14Is Genfit (EPA:GNFT) A Risky Investment?
Nov 28Revenue & Expenses Breakdown
How Genfit makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 80 | 22 | 20 | 40 |
31 Mar 24 | 57 | -3 | 19 | 43 |
31 Dec 23 | 34 | -29 | 19 | 47 |
30 Sep 23 | 32 | -32 | 18 | 45 |
30 Jun 23 | 29 | -34 | 18 | 44 |
31 Mar 23 | 28 | -29 | 18 | 40 |
31 Dec 22 | 26 | -24 | 17 | 36 |
30 Sep 22 | 60 | 12 | 18 | 33 |
30 Jun 22 | 94 | 48 | 18 | 30 |
31 Mar 22 | 90 | 58 | 18 | 32 |
31 Dec 21 | 85 | 67 | 18 | 35 |
30 Sep 21 | 46 | 14 | 17 | 40 |
30 Jun 21 | 6 | -39 | 16 | 45 |
31 Mar 21 | 7 | -70 | 21 | 52 |
31 Dec 20 | 9 | -101 | 25 | 59 |
30 Sep 20 | 24 | -84 | 31 | 62 |
30 Jun 20 | 39 | -67 | 36 | 64 |
31 Mar 20 | 39 | -66 | 34 | 65 |
31 Dec 19 | 39 | -65 | 31 | 66 |
30 Sep 19 | 23 | -80 | 24 | 70 |
30 Jun 19 | 8 | -94 | 18 | 74 |
31 Mar 19 | 8 | -87 | 14 | 70 |
31 Dec 18 | 7 | -80 | 10 | 67 |
30 Sep 18 | 7 | -75 | 10 | 65 |
30 Jun 18 | 7 | -70 | 11 | 63 |
31 Mar 18 | 7 | -63 | 10 | 58 |
31 Dec 17 | 7 | -56 | 9 | 54 |
30 Sep 17 | 7 | -50 | 8 | 49 |
30 Jun 17 | 8 | -44 | 7 | 44 |
31 Mar 17 | 7 | -39 | 8 | 39 |
31 Dec 16 | 7 | -34 | 8 | 33 |
30 Sep 16 | 6 | -27 | 8 | 26 |
30 Jun 16 | 5 | -21 | 7 | 20 |
31 Mar 16 | 5 | -19 | 6 | 18 |
31 Dec 15 | 4 | -17 | 6 | 16 |
30 Sep 15 | 5 | -17 | 4 | 19 |
30 Jun 15 | 5 | -17 | 3 | 23 |
31 Mar 15 | 6 | -17 | 5 | 20 |
31 Dec 14 | 7 | -17 | 6 | 18 |
30 Sep 14 | 7 | -15 | 7 | 11 |
30 Jun 14 | 7 | -14 | 8 | 5 |
31 Mar 14 | 6 | -13 | 8 | 2 |
31 Dec 13 | 6 | -13 | 7 | 0 |
Quality Earnings: GNFT has a high level of non-cash earnings.
Growing Profit Margin: GNFT became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GNFT has become profitable over the past 5 years, growing earnings by 38.1% per year.
Accelerating Growth: GNFT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GNFT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: GNFT's Return on Equity (22.9%) is considered high.